Session Type: ACR Concurrent Abstract Session
Session Time: 4:30PM-6:00PM
Conclusion: This first analysis shows PD differences consistent with the expected MoA of abatacept and adalimumab. Further analysis of this rich time course dataset may reveal predictive biomarkers of response and disease progression, and novel targets for therapeutics.
1. Subramanian A, et al. Proc Natl Acad Sci U S A 2005;102:15545–50.
2. Gaujoux R, et al. Bioinformatics 2013;29:2211–2.
To cite this abstract in AMA style:Jabado O, Maldonado M, Schiff M, Weinblatt M, Fleischmann R, Robinson WH, Greenfield A, Connolly S. Pharmacodynamic Analysis of Whole Blood Gene Expression over 2 Years in a Phase IIIb Head-to-Head Trial of Abatacept and Adalimumab in Patients with RA [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/pharmacodynamic-analysis-of-whole-blood-gene-expression-over-2-years-in-a-phase-iiib-head-to-head-trial-of-abatacept-and-adalimumab-in-patients-with-ra/. Accessed November 18, 2019.
« Back to 2017 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/pharmacodynamic-analysis-of-whole-blood-gene-expression-over-2-years-in-a-phase-iiib-head-to-head-trial-of-abatacept-and-adalimumab-in-patients-with-ra/